In Brief: Beconase Rx-to-OTC switch
Beconase Rx-to-OTC switch: FDA's Nonprescription Drugs and Pulmonary & Allergy Drugs Advisory committees will review Glaxo Wellcome's switch NDA (20-840) for beclomethasone dipropionate nasal spray .042% on Sept. 19 for OTC treatment and prevention of seasonal allergic rhinitis symptoms in patients over the age of 12. The meeting will begin at 8:30 a.m. at the Gaithersburg, Md. Holiday Inn...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth